Literature DB >> 23826412

Evolution in the diagnosis and treatment of autoimmune pancreatitis: experience from a single tertiary care center.

Alper Yurci1, Tyler Stevens, Shetal N Shah, Ryan E Law, Matthew R Walsh, Lisa Yerian, Xiuli Liu.   

Abstract

BACKGROUND: Autoimmune pancreatitis (AIP) is a recently characterized disease with specific clinical, radiographic, and histological features. These diagnostic features have been codified in the recently revised HISORt criteria. The aim of this study was to determine how the recognition and management of AIP has evolved at our center since the publication of the HISORt criteria in 2006.
METHODS: We conducted a historical cohort study consisting of patients with AIP based on the revised HISORt criteria seen at our tertiary care center since 1990. Cases were identified from pathology, laboratory, and pancreas clinic databases. The medical records were reviewed to ascertain demographic and clinical characteristics, radiologic and laboratory results, and patient outcomes. When available, prior images and pathology slides were retrospectively reviewed. The clinical outcomes of the patients were assessed following surgical or medical treatment, and compared based on the calendar year of presentation (before or after 2006).
RESULTS: Forty-seven cases were identified based on the revised HISORt criteria. Of these, 22 were evaluated before and 25 after January 1, 2006. In the early cohort, the diagnosis was frequently missed, including 15 patients that underwent surgical resections. None from the early cohort had a serum IgG4 drawn or mention of possible AIP in the imaging reports. When histology was obtained, the surgical pathologist did not perform IgG4 or Movat stain to allow a histological diagnosis of AIP. Several patients developed diabetes (n=3), calcific pancreatitis with exocrine insufficiency (n=3), proximal biliary strictures (n=7), and pancreatic cancer (n=1) during follow-up. In contrast, patients in the late cohort were less likely to undergo a surgical resection that the early cohort (36% vs. 68%, p=0.042). They were more likely to have a serum IgG4 drawn (80% vs. 0%) and to undergo a corticosteroid trial (44% vs. 0%, p=0.0003). 10/11 patients (92%) who underwent corticosteroid trials had resolution of their symptoms and improvement in structural abnormalities on imaging.
CONCLUSION: A growing multidisciplinary awareness of AIP has led to improved diagnostic evaluation, prompter diagnosis, fewer surgical resections, and more frequent corticosteroid trials.

Entities:  

Keywords:  Autoimmune pancreatitis; IgG4; corticosteroid; resection

Mesh:

Substances:

Year:  2013        PMID: 23826412      PMCID: PMC3693196     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  13 in total

Review 1.  Autoimmune pancreatitis and IgG4-related sclerosing disease.

Authors:  Terumi Kamisawa; Kensuke Takuma; Naoto Egawa; Koji Tsuruta; Tsuneo Sasaki
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-15       Impact factor: 46.802

2.  Risk factors for pancreatic stone formation in autoimmune pancreatitis over a long-term course.

Authors:  Masahiro Maruyama; Norikazu Arakura; Yayoi Ozaki; Takayuki Watanabe; Tetsuya Ito; Suguru Yoneda; Masafumi Maruyama; Takashi Muraki; Hideaki Hamano; Akihiro Matsumoto; Shigeyuki Kawa
Journal:  J Gastroenterol       Date:  2011-12-21       Impact factor: 7.527

Review 3.  Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis.

Authors:  K Yoshida; F Toki; T Takeuchi; S Watanabe; K Shiratori; N Hayashi
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

4.  IgG4-positive plasma cell infiltration in the diagnosis of autoimmune pancreatitis.

Authors:  Lizhi Zhang; Kenji Notohara; Michael J Levy; Suresh T Chari; Thomas C Smyrk
Journal:  Mod Pathol       Date:  2006-09-15       Impact factor: 7.842

5.  Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience.

Authors:  Suresh T Chari; Thomas C Smyrk; Michael J Levy; Mark D Topazian; Naoki Takahashi; Lizhi Zhang; Jonathan E Clain; Randall K Pearson; Bret T Petersen; Santhi Swaroop Vege; Michael B Farnell
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-14       Impact factor: 11.382

6.  Diagnosis of autoimmune pancreatitis by core needle biopsy: application of six microscopic criteria.

Authors:  Sönke Detlefsen; Asbjørn Mohr Drewes; Mogens Vyberg; Günter Klöppel
Journal:  Virchows Arch       Date:  2009-02-24       Impact factor: 4.064

7.  Autoimmune pancreatitis: imaging features.

Authors:  Dushyant V Sahani; Sanjeeva P Kalva; James Farrell; Michael M Maher; Sanjay Saini; Peter R Mueller; Gregory Y Lauwers; Carlos D Fernandez; Andrew L Warshaw; Joseph F Simeone
Journal:  Radiology       Date:  2004-09-30       Impact factor: 11.105

Review 8.  Autoimmune pancreatitis: an illustrated guide to diagnosis.

Authors:  R D Proctor; C J Rofe; T J C Bryant; C N Hacking; B Stedman
Journal:  Clin Radiol       Date:  2012-11-21       Impact factor: 2.350

9.  A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer.

Authors:  Suresh T Chari; Naoki Takahashi; Michael J Levy; Thomas C Smyrk; Jonathan E Clain; Randall K Pearson; Bret T Petersen; Mark A Topazian; Santhi S Vege
Journal:  Clin Gastroenterol Hepatol       Date:  2009-05-04       Impact factor: 11.382

10.  Pancreatic ductal adenocarcinoma associated with autoimmune pancreatitis.

Authors:  Raffaele Pezzilli; Silvia Vecchiarelli; Maria Cristina Di Marco; Carla Serra; Donatella Santini; Lucia Calculli; Dario Fabbri; Betzabè Rojas Mena; Andrea Imbrogno
Journal:  Case Rep Gastroenterol       Date:  2011-07-09
View more
  2 in total

Review 1.  [Diseases in gastroenterology].

Authors:  A Göke; B Göke
Journal:  Internist (Berl)       Date:  2013-10       Impact factor: 0.743

2.  Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry.

Authors:  Ji Zongfei; Zhang Lijuan; Sun Ying; Liu Dongmei; Wu Sifan; Kong Xiufang; Ma Lingying; Liu Yun; Ma Lili; Chen Huiyong; Jiang Lindi
Journal:  Ther Adv Chronic Dis       Date:  2021-06-30       Impact factor: 5.091

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.